Malvern Biotech Races to Raise $15M Before Make-or-Break Alzheimer's Data

Malvern-based Annovis Bio is urgently seeking to raise $15 million by the end of 2026 to fund an ongoing late-stage Phase 3 trial for its Alzheimer’s drug buntanetap, with key trial data expected in March 2027 that will determine further funding and commercialisation strategy.

This Wire brief sits within Fusion42's coverage of Biotech.